Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Engineering modified sirna

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Presentation
  • By: KOKIL, Ganesh (The University of queensland, Pharmacy Australia Centre of Excellence, Brisbane, Australia)
  • Co-author(s): Glanfield, Amber (The Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia)
    Veedu, Rakesh (School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia)
    Wengel, Jesper (NAC, Department of Physics, Chemistry and Pharmacy, University of Sout. Denmak, Odense campusvej, Denmark)
    Ramm, Grant (The Hepatic Fibrosis Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia)
    Parekh, Harendra (School of Pharmacy,PACE, The University of Queensland, Brisbane, Australia)
  • Abstract:

    The global prevalence of diabetes mellitus presently sits at over 380 million, of which T2DM accounts ≈90% cases. In T2DM, insulin resistance (IR) reduces tissue glucose uptake accompanied by an increase in hepatic glucose production. Protein tyrosine phosphatase 1B (PTP-1B) acts as a key driver of IR. Thus, silencing the PTP-1B gene with RNAi..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses